What's Happening?
AN2 Therapeutics reported its financial results for the first quarter of 2026, highlighting progress in its clinical programs. The company is advancing its oral epetraborole program for polycythemia vera into Phase 2, with plans to initiate the trial
in Q3 2026. AN2 also commenced a Phase 2 trial for M. abscessus lung disease and completed dosing in a Phase 1 trial for its Chagas disease program. The company declared its ENPP1 candidate for solid tumors, marking a transition from early research to development. AN2 reported a net loss of $10 million for the quarter, with cash and investments totaling $85.3 million.
Why It's Important?
AN2 Therapeutics' pipeline progress demonstrates its commitment to addressing unmet medical needs in hematologic diseases, infectious diseases, and oncology. The advancement of its epetraborole program for polycythemia vera and the initiation of trials for M. abscessus lung disease and Chagas disease highlight the company's strategic focus on leveraging its boron chemistry platform. The financial results and strong cash position provide a foundation for AN2 to continue its research and development efforts, with the potential to deliver impactful therapies to patients.
What's Next?
AN2 Therapeutics plans to advance three programs into Phase 2 development in 2026, with multiple data readouts expected within its cash runway into 2029. The company will focus on progressing its clinical trials and exploring the potential of its boron chemistry platform in oncology and bone disorders. These efforts will be crucial in determining the future commercial potential of AN2's pipeline and its impact on the company's growth trajectory.
